Human Immunodeficiency Virus Clinical Trial
Official title:
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
This study is being done to compare three strategies to deliver HCV treatment with
ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by
mouth daily for 12 weeks. The study population is persons living with HIV and hepatitis C
virus (HCV) coinfection who also use drugs. Participants will be randomized into one of three
treatment groups:
1. Usual care in the clinic. This treatment group will receive the standard of care for HCV
treatment from their health care team.
2. Usual care plus peer-mentors. In addition to the usual care, this is an investigational
strategy in which participants assigned to this group will be asked to interact with a
peer-mentor who is someone who has been cured of their HCV infection.
3. Usual care plus incentives. In addition to the usual care, this is an investigational
strategy in which participants assigned to this group will be given incentives after
completing certain treatment goals during the course of the study.
HCV treatment with ledipasvir/sofosbuvir is considered the standard of care for HCV and is
recommended by experts in liver disease and infectious diseases.
Recent advances in Hepatitis C Virus (HCV) treatment represent a paradigm shift for the
treatment of HCV-infected persons with Human Immunodeficiency Virus (HIV) coinfection. With
potent antiviral activity, excellent safety/tolerability, few drug interactions and once
daily, oral dosing, Sofosbuvir (SOF)/Ledipasvir (LDV) have had excellent efficacy in
randomized controlled trials and offer great promise for the treatment of hepatitis C in
HIV/HCV coinfected patients who are at high risk for progressive liver disease and
HCV-related mortality. While the availability of SOF/LDV has great promise for the treatment
of patients, the experience with antiretroviral therapy (ART) for the treatment of HIV
infection indicates that interferon-free oral therapy is necessary but not sufficient to cure
HCV in the real world. While removal of Interferon increases the proportion of coinfected
persons who use drugs (PWUD) eligible for treatment, multiple barriers will remain (e.g.,
medical/psychiatric illness, substance abuse, and social constraints). Effective ART in
coinfected PWUDs provides a strategic framework for the delivery of curative HCV treatment;
novel and effective strategies for delivering this care for HCV must be evaluated, including
incentives and peer-mentoring.
Financial incentives. One method for increasing delivery of care is the contingent
administration of monetary incentives; such reinforcements have improved health outcomes
related to drug/alcohol abstinence, smoking cessation, childhood vaccination, tuberculosis
care and HIV treatment. Contingent reinforcement has also been successfully used to link
HIV-infected patients to care and improve adherence to ART. Curative HCV treatments are given
for a finite duration (12 weeks) which offers an ideal paradigm for incentive interventions
by reducing the overall cost and removing concerns of loss of adherence if incentives are
stopped.
Peer support. A second method for improving delivery of care is the use of peers or
laypersons with the same illness. By matching on cultural competencies and establishing
trust, peers may be particularly effective in some settings. In one study, African American
veterans with poorly controlled diabetes assigned to peer-support had better glucose control
than those assigned financial incentives. Coinfected patients may benefit from peer support.
The investigators will test two innovative strategies to improve HCV treatment outcomes in
HIV/HCV coinfected patients through the delivery of SOF/LDV for 12 weeks as part of a
randomized controlled trial. HIV-infected patients will receive SOF/LDV under one of three
randomly assigned conditions: usual care (clinic-based nursing model), incentive care (IC) or
peer-mentor care (PMC).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |